[Special Stock] Aju IB Investment, Huron Receives FDA Approval for Parkinsonism Diagnostic Medical AI, Trading Suspension

[Asia Economy Reporter Lee Seon-ae] The stock price of Aju IB Investment is soaring.

As of 10:48 AM on the 21st, Aju IB Investment is trading at 3,225 KRW, up 11.35% from the previous trading day. It is showing a sharp rise, with a VI triggered during the session. The price surged up to 3,250 KRW.

It is interpreted that the surge occurred after Huron, a medical artificial intelligence (AI) company, announced that it had obtained approval from the U.S. Food and Drug Administration (FDA) for its Parkinson's disease brain lesion visualization AI solution product, ‘Veuron-Brain-mN1’. Aju IB Investment is a key player often mentioned when discussing Huron's growth process. It is evaluated as having played a foundational role in Huron’s growth by making consecutive investments.

Huron’s new product visualizes brain lesions (Nigrosome 1), known as diagnostic biomarkers for Parkinson’s disease symptoms, through AI learning from MR images. It is known that visual interpretation was difficult with previously used technologies. The company explained that obtaining FDA certification for ‘mN1’ has opened a green light for entry into the U.S. market following Korea and Europe, and that it plans to actively pioneer the global market for three brain diseases (Parkinson’s, dementia, stroke) in the future. Huron’s mN1 received domestic Class 2 medical device certification from the Ministry of Food and Drug Safety in May 2020 and obtained European CE certification in May last year.

Shin Dong-hoon, CEO of Huron, said, "Huron provides core diagnostic information for brain neurological diseases based on medical imaging through AI. Despite being a market with high entry barriers worldwide, we present accurate and novel diagnostic methods based on our technological capabilities, so the potential for future development is very high."

This content was produced with the assistance of AI translation services.